Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/EUCTR2004-004072-37-IT
EUCTR2004-004072-37-ITActive, not recruitingNot Applicable

CETUXIMAB AND FOLFIRI AS FIRST-LINE TREATMENT OF LOCALLY ADVANCED AND METASTATIC GASTRIC CANCER

AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI0 sites25 target enrollmentStarted: April 21, 2006Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Drugs

Trial Snapshot

Phase
Not Applicable
Status
Active, not recruiting
Sponsor
Enrollment
25
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional clinical trial of medicinal product

Eligibility Criteria

Sex
All

Inclusion Criteria

  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1.2 Adults (18-64 years) yes
  • •F.1.2.1 Number of subjects for this age range
  • •F.1.3 Elderly (>=65 years) yes
  • •F.1.3.1 Number of subjects for this age range

Exclusion Criteria

  • Not provided

Investigators

Sponsor
AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI

Similar Trials

Completed
Phase 2
Conversion therapy of Cetuximab plus FOLFIRI followed by Bevacizumab plus mFOLFOX6 in patients with liver metastatic colorectal cancer
JPRN-UMIN000004694agoya Surgical Oncology Group50
Active, not recruiting
Phase 1
Phase II study on the use of the FOLFIRI + Cetuximab association in the first-line treatment of patients with advanced colorectal carcinoma with wild type RAS and FcYRIIIA-V / Vadvanced colorectal carcinoma with wild type RAS and FcyRIIIA-V / V
EUCTR2018-003778-29-ITIstituto Nazionale Tumori G. Pascale34
Recruiting
Phase 2
PhaseII study of Combination FOLFIRI with Cetuximab in patients with advanced/metastatic colorectal cancer previously received oxaliplatin-based chemoterapy.Colorectal Cancer
JPRN-UMIN000007372Kurume University School of medicine, Department of Surgery30
Active, not recruiting
Not Applicable
First line treatment with Rituximab asociated to CVP plus Interferon in Follicular Lymphoma. Phase II study.Asociación de Rituximab al esquema CVP + Interferón en el tratamiento de primera línea del linfoma folicular - R-CVP-IF
EUCTR2005-004761-42-ESFundacion Leucemia y Linfoma
Active, not recruiting
Phase 1
PHASE II STUDY OF CETUXIMAB FOR THE TREATMENT OF REFRACTORY OR RELAPSED MULTIPLE MYELOMA EMMA-1 (ERBITUX FOR MULTIPLE MYELOMA) - EMMA-1Relapsed or refractory multiple myeloma
EUCTR2005-005612-24-DEniversity of Cologne